When does biktarvy go off patent?

Patents for Biktarvy are country-specific, so there isn’t a single global “goes off patent” date.

- In the United States: Biktarvy is covered by multiple patents (including composition-of-matter patents on bictegravir and patents on the fixed-dose combination FTC/TAF, plus potential method/formulation patents and term extensions). The earliest expiries are expected in the early-to-mid 2030s, with some protections potentially extending into the late 2030s due to patent term extensions. There is also regulatory data exclusivity for a new molecular entity, which typically lasts about 5 years after approval; this would have ended around 2023–2024, but patents continue longer.
- In other countries: expiry dates vary by jurisdiction and depend on local patent filings, extensions, and any litigation outcomes.

If you want precise dates for a specific country, tell me which country you’re interested in and I can point you to the current patent/exclusivity status (for example, the FDA’s Orange Book for the US or national patent databases). I can also guide you on how to look this up yourself.